Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new clinician-reported data in patients with intellectual and developmental disabilities demonstrating meaningful and rapid improvements in tardive dyskinesia severity, as well as improvements in overall functional status, including physical and socio-emotional outcomes, with INGREZZA® (valbenazine) capsules. The findings were presented at the American Academy of Developmental Medicine and Dentistry's 24th Annual Education Conference in Dallas.